A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation
PurposeTheranostics integrates diagnostic imaging (e.g., 18F-PSMA-1007 PET) with targeted radioligand therapy (TRT; e.g., 177Lu-PSMA-617), but personalized dosimetry remains challenging due to complex dose calculations. Current methods like Monte Carlo simulations are accurate but require impractica...
Saved in:
| Main Authors: | Thanh Tai Duong, Danny De Sarno, Hatim Fakir, Glenn Bauman, Martin Martinov, Rowan M. Thomson, Ting-Yim Lee |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1600821/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01) -
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01) -
Comparison of tumour segmentation methods for dosimetry in [177Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer
by: Peter Frøhlich Staanum, et al.
Published: (2025-07-01) -
Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01) -
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
by: Aaron R. Hansen, et al.
Published: (2025-01-01)